CELEBRATING 20 YEARS OF TRANSFORMATIVE STEM CELL RESEARCH
DIVE INTO THE DIGITAL REPORT

Newsroom

Researchers will focus on an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV-infected cells like this one.
At left, image shows white blood cells (red) from one of the X-CGD clinical trial participants before gene therapy. At right, after gene therapy, white blood cells from the same patient show the presence of the chemicals (blue) needed to attack and destroy bacteria and fungus.
Dr. Sarah Larson (left) and Yvonne Chen
Photograph of Dr. Steven Jonas
Led by Dr. Donald Kohn and Katelyn Masiuk, the researchers engineered a “viral vector” that would turn on the FoxP3 gene only in regulatory T cells — and not in other types of cells.
Patient-specific human induced pluripotent stem cell-derived retinal pigment epithelium cells.
Hussein El Kerdi during his 2016 procedure at UCLA. His father, Ali El Kerdi (with cell phone) looks on.
UCLA professors Huan Meng, Melissa Spencer and April Pyle pictured in a lab.
From left: April Pyle, Courtney Young and Melissa Spencer
Primed human embryonic stem cells (purple) surrounded by a stem cell surface marker (green), which would be missing in naïve embryonic stem cells.